Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
04 2020
Historique:
received: 08 10 2019
revised: 21 01 2020
accepted: 21 01 2020
pubmed: 25 1 2020
medline: 28 7 2020
entrez: 25 1 2020
Statut: ppublish

Résumé

Epidemiological research in multiple sclerosis (MS) has mainly been performed in socioeconomically and ethnically limited populations; influences on MS risk have not been studied in prospectively collected non-White populations. We set out to study the influence of previously described MS risk factors in an ethnically diverse population. A nested case-control study was created using primary care records of >1 million individuals, >50% of whom identify as Black, Asian, and Minority Ethnic (BAME). MS cases were compared to an age- and sex-matched control cohort (1:4), and to a large unmatched cohort. Odds ratios (ORs) of disease were determined according to exposure of interest, and a multivariate model including all exposures was created. Potential pairwise interactions were considered where both indicated a significant effect. A total of 1,344 confirmed MS cases were included. MS OR in blacks aged <40 years was 1.15 (95% confidence interval [CI] = 0.81-1.62) compared to whites. MS odds in BAME current (OR = 1.71, 95% CI = 1.24-2.31) and ex-smokers (OR = 2.83, 95% CI = 2.14-3.72) were considerably higher than in Whites (OR = 1.09, 95% CI = 0.88-1.34; OR = 1.44, 95% CI = 1.19-1.74, respectively). Prior infectious mononucleosis was associated with increased odds of MS in Blacks (OR = 4.94, 95% CI = 1.23-17.89). An increase in MS odds was seen in the least-deprived quintile (OR = 2.46, 95% CI = 1.40-4.24), but no effect across deprived quintiles was seen. This cohort provides novel data on factors potentially driving MS susceptibility in a diverse population, one-third of whom live in poverty. Environmental exposures have differential risk across ethnicity. ANN NEUROL 2020;87:599-608.

Identifiants

pubmed: 31975487
doi: 10.1002/ana.25688
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

599-608

Informations de copyright

© 2020 American Neurological Association.

Références

Simon KC, van der Mei IAF, Munger KL, et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010;74:1365-1371.
Hedström AK, Olsson T, Alfredsson L. Body mass index during adolescence, rather than childhood, is critical in determining MS risk. Mult Scler 2016;22:878-883.
Manrai AK, Funke BH, Rehm HL, et al. Genetic misdiagnoses and the potential for health disparities. N Engl J Med 2016;375:655-665.
Langer-Gould A, Wu J, Lucas R, et al. Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: a multiethnic study. Neurology 2017;89:1330-1337.
Langer-Gould A, Lucas R, Xiang AH, et al. MS Sunshine Study: sun exposure but not vitamin D is associated with multiple sclerosis risk in blacks and Hispanics. Nutrients 2018;10. pii: E268.
Munk Nielsen N, Corn G, Frisch M, et al. Multiple sclerosis among first- and second-generation immigrants in Denmark: a population-based cohort study. Brain 2019;142:1587-1597.
Hedström AK, Olsson T, Alfredsson L. Smoking is a major preventable risk factor for multiple sclerosis. Mult Scler 2016;22:1021-1026.
Hedström AK, Hössjer O, Katsoulis M, et al. Organic solvents and MS susceptibility: interaction with MS risk HLA genes. Neurology 2018;91:e455-e462.
Disanto G, Zecca C, MacLachlan S, et al. Prodromal symptoms of multiple sclerosis in primary care. Ann Neurol 2018;83:1162-1173.
Wijnands JM, Zhu F, Kingwell E, et al. Five years before multiple sclerosis onset: phenotyping the prodrome. Mult Scler 2019;25:1092-1101.
Mathur R, Bhaskaran K, Chaturvedi N, et al. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health 2014;36:684-692.
Belbasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 2015;14:263-273.
Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 2017;13:25-36.
Berg-Hansen P, Moen SM, Sandvik L, et al. Prevalence of multiple sclerosis among immigrants in Norway. Mult Scler 2015;21:695-702.
Berg-Hansen P, Celius EG. Socio-economic factors and immigrant population studies of multiple sclerosis. Acta Neurol Scand 2015;132:37-41.
Albor C, du Sautoy T, Kali Vanan N, et al. Ethnicity and prevalence of multiple sclerosis in East London. Mult Scler 2017;23:36-42.
Keiding N, Clayton D. Standardization and control for confounding in observational studies: a historical perspective. Stat Sci 2014:29:529-558.
Atkinson MD, Kennedy JI, John A, et al. Development of an algorithm for determining smoking status and behaviour over the life course from UK electronic primary care records. BMC Med Inform Decis Mak 2017;17:2.
GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:269-285.
Baker C. Population estimates & GP registers: why the difference? Available at: https://commonslibrary.parliament.uk/social-policy/health/population-estimates-gp-registers-why-the-difference/.
Mokry LE, Ross S, Timpson NJ, et al. Obesity and multiple sclerosis: a Mendelian randomization study. PLoS Med 2016;13:e1002053.
Bove R, Musallam A, Xia Z, et al. Longitudinal BMI trajectories in multiple sclerosis: sex differences in association with disease severity. Mult Scler Relat Disord 2016;8:136-140.

Auteurs

Ruth Dobson (R)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London.
Department of Neurology, Royal London Hospital.

Mark Jitlal (M)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London.

Charles R Marshall (CR)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London.
Department of Neurology, Royal London Hospital.

Alastair J Noyce (AJ)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London.
Department of Neurology, Royal London Hospital.

John Robson (J)

Department of Primary Care, Queen Mary University of London.

Jack Cuzick (J)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London.

Gavin Giovannoni (G)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London.
Department of Neurology, Royal London Hospital.
Blizard Institute, Queen Mary University of London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH